Skip to Main Content

Paper Details

Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma.
JCO Precis Oncol
35
2019
BRAF, BRAF V600E, BRAF V600E ctDNA, BRAF V600E mutation, BRAF-mutant tumors, C228T, C250T, Circulating Cell-Free Tumor DNA, Metastatic Melanoma, NRAS, NRAS Q61, NRAS Q61 ctDNA, NRAS-mutant ctDNA, TERT C228T, TERT C250T, V600E, advanced-stage melanoma, cell-free tumor DNA, ctDNA, lactate, lactate dehydrogenase, melanoma, metastatic melanoma, mitogen-activated protein kinase, patient, patients, plasma, plasma ctDNA, plasma-derived ctDNA, serum S100, systemic disease, tumor
Author NameAffiliation
J??r??mie NsengimanaLeeds Institute of Cancer and Pathology,University of Leeds
Antje SuckerUniversity Hospital of Essen, University Duisburg-Essen and German Cancer Consortium partner site Essen/Dusseldorf
Dirk SchadendorfUniversity Hospital of Essen, University Duisburg-Essen and German Cancer Consortium partner site Essen/Dusseldorf
  • 1 - 3

Datasets

Release 1.2